Cancer Cell Panel Screening
Well-validated in vitro screening program for rapid and
cost-effective screening of ~500 cell lines
Progress your Lead Compound to Validated Candidate with our Expanded Cancer Cell Panel Screening
Use cost-effective, rapid, and large-scale cancer cell line screening to advance your lead compound to validated candidate. Cancer Cell Panel Screening provides key information on the cytotoxicity and chemotherapeutic potential of your agent early in the drug development process.
| Registration Deadline | Study Initiation |
|---|---|
| February 13, 2026 | February 25, 2026 |
| April 24, 2026 | May 5, 2026 |
| July 3, 2026 | July 13, 2026 |
| September 28, 2026 | October 8, 2026 |
| December 4, 2026 | December 14, 2026 |
| February 1, 2027 | February 14, 2027 |
Choose from the Largest Selection of Licensed Oncology Cell Lines
Take advantage of our quarterly revival of ~500 cancer cell lines, providing you significant cost savings.
Highlights of Cancer Cell Panel Screening
- High throughput screening of at least 50 cell lines per run to maximize your savings
- Positive drug control and cell line revival costs are included as part of Cancer Cell Panel Screening
- Unique subpanels built from Crown Bioscience’s proprietary menu of ~500 cancer cell lines
- Enhanced cell line growth data for improved screening quality including:
- Validated seeding densities across multiple time points
- Choose the models that best fit your needs with our curated, online database of cancer cell lines
- Select from quality cells STR verified and mycoplasma-proofed
- Customize your study with flexible template designs
- Quality control your data against standard of care agents
- Obtain bioinformatics support throughout the study
- Review your data in real time using a secure online client account

Cancer Cell Panel Screening: Crown Bioscience’s Large-Scale Cell Line Screening Panel Platform
Focused Screening Panels
Our Cancer Cell Panel Screening cancer cell line panels include:
-
A genomically diverse and growing collection of ~500 cancer cell lines for drug response screening
-
A diverse oncogenic in vitro screening panel of more than 150 well validated cell lines with corresponding xenograft models ready for in vivo efficacy studies
-
A RNAseq panel with more than 170 in-house genomically characterized cell lines to correlate mutation status, copy number variation, and expression levels with drug response.
-
PDX-derived cell line panels: Access to over 35 unique human disease-relevant cell lines derived from our patient-derived xenograft (PDX) models.
